Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It isn't possible for ViaDerma to make an amendment to a published patent application in the name of inventors other than himself.
Read my stickie. The USPTO won't even discuss the Phillips/Keough patent-pending invention with anyone but the two named inventors.
"The U.S. Patent Application published as US 20130190274 was dropped by Phillips.
This is why ViaDerma filed a new provisional patent two months ago. " While VDRM filed a new provisional patent, it made an amendment to the original filing (an improvement), which made this VDRM provisional patent filing unique.
Please share the email exchange between you and Otiko in which he acknowledged his belief the Phillips/Keough patent-pending application for the transdermal delivery system was "dropped" and that he can file a new application for this technology.
Can you confirm whether the future state products announced in news releases are based on this invention?
The U.S. Patent Application published as US 20130190274 was dropped by Phillips.
This is why ViaDerma filed a new provisional patent two months ago.
MM's reported 57.41% short sale volume today. Surprised? Nope.
http://otcshortreport.com/?index=CGRA&action=view
Wrong. ViaDerma is the labeler. They pay Phillips Company for the non-exclusive right to manufacture Viabecline at Phillips facility in Oklahoma, and to distribute it. This info is in the December 2016 Quarterly Report.
Below is a link to a shareholder communication with the two transdermal delivery system inventors: Steven J. Keough and Howard Phillips. Otiko works with Phillips.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129232062
They had to alter the formula for Viabecline to avoid similarities with Diabecline as the Diabecline Trademark is held by Keough. The ingredients are noted in my section of the iBox. Diabecline won the Edison Award in 2012.
Outdated product Diabecline. lol Viabecline is new and all VDRM 100% ready to go to market with FDA approval, this product alone is worth the company MILLIONS of dollars.
Lead Product Viabecline: World’s strongest broad spectrum tetracycline-based topical antibiotic with proven results.
www.viadermalicensing.com/
http://www.viadermalicensing.com/img/ViaDermaCaseStudies.pdf
Coast to Coast Podiatry is a private corporation registered to Mr. and Mrs. Otiko. They use the same office address as ViaDerma Licensing, a public corporation.
ViaDerma pays $10,000 per year for this space. Who receives the rent check?
Coast to Coast is likely the main contributor to ViaDerma revenues.
Otiko issued a news release a year ago announcing Coast to Coast as a Distributor. He did not disclose that he and his wife ARE Coast to Coast.
The SG&A budget shows ~50k per quarter. I am certain the Otiko's, as Directors, along with brother Manny, are pulling a salary.
This has been going on since ViaDerma became a public entity in 2014, soon after the Otiko's married.
The Annual Report will likely show a loss, and about a 200M increase in unrestricted shares. We don't know if shares were used to pay the six-figure debt noted in the last Q's. Where did the shareholder money go in the past year?
Q1 2017 will show an increase of ~20-30M shares outstanding, the Float, and a few million coming off restriction. There will probably be no revenue in Q1 other than what Coast to Coast may pay to ViaDerma.
ViaDerma pays Phillips Company for a non-exclusive right to manufacture and distribute (label) Viabecline, which is a clone of a five-year old product named Diabecline.
ViaDerma's "products" are based on the Phillips/Keough patent-pending transdermal delivery system referenced in my stickie. They have no innovative transdermal system under their name(s).
The Annual Report should clearly convey the above information.
This upcoming approval is only a bonus on the fact that we have Viabecline hitting market very soon, "a rollout of its FDA registered drug, Viabecline topical antibiotic" "The Company expects sales for 2017 to be about 500,000 units" at $125 per 5ml bottle, with a wholesale price to be established for the Clinics & Wound Care Centers."
We also have Onychomycosis which "Onychomycosis Clinical Studies Show Significant Results" and other products coming! This company will be worth over $1 in a short time. We have products that rival OWCP and CNBX which all started the same way at or below .01.
"Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream."
Our main office is located at 6650 Reseda Blvd, Suite 101A, Reseda, CA 91335, which we use for daily operations, marketing, research and development
The office is approximately 800 square feet with annual rental expense of approximately $10,000. We believe the current office space is sufficient for the next 12 months
Our official business mailing address is 4640 Admiralty Way, Suite 500, Marina Del Rey, California 90292
Read my messages. I don't like to repeat myself.
Provide me real reasons why you think that to be so and you can convert me. But thanks for your opinion it is always welcomed.
Fundamentals suck though...which is why I flip and use stops.
One of the best TA setups on the OTC right now
I see fraudulent representation and lack of transparency. For that reason, I place this company in the bottom 10% of stocks I researched.
Still waiting for the Annual Report.
Better than 90% of pinks Xp
"The Company remains committed to developing its business plan without the issuance of stock."
Last Share Issuance - November 12, 2015
Authorized 500,000,000
Issued & Outstanding 391,413,019
Restricted 132,349,027
Float 259,063,992
Shares Confirmed by Transfer Agent on April 6, 2017
We have confirmed one product named Viabecline that they can sell under a non-exclusive patent license agreement. What other products do they sell today?
THIS COMPANY IS WORTH OVER .25-.50 easy with the products they already have out.
Awesome! Actually bought in mid-March, and added last week. Looks like a winner to me!
Always glad to see you hear. I grabbed a position on Friday. :)
Read the boring filings if you really want to know.
We agree the fins reflect line item details of assets needed to manufacture AND CBD products. We agree the company has a co-pack agreement in place. We agree the labels have been finalized. We agree the product has been scheduled for a production run.
If all of the pieces to the product puzzle mentioned above didn't exist, we could agree there is no product. But..they do exist so there really is product.
On a side note, I don't like repeating my messages, and I know readers don't like repetitive messages so this exchange is done.
The numerous responses I gave over the past year still apply.
All is well in CGRA land.
Did I say the AND CBD products were for sale today? Nope. I simply directed you to the product website. Hope you enjoyed it as much as I did.
Did I say I wasn't concerned about the share structure? Yep!
I see a CBD product I want to buy. I read the fins, did a basic integrity check on the CEO. He knows the biz and successfully brought top sellers to market.
I buy under MY rules.
Agreed! I really want these products chilling in my frig...like right now.
AND...My shares will chill in my accounts after I cover costs.
Yep .. And many more in the works. That's why we have to stick with the program both short and long term. This stock should stay in our portfolio for a while and we should probably hold some of it for the long term if you read all the future expansion plans
I found products through their recent news release. I really liked what I saw on their product website--Antioxidant Nutritious Drinks with CBD so I took a position after some basic DD.
Check it out! http://www.anddrinks.com
I don't mind the CEO holding half of the outstanding shares. The float meets my personal standard--under 500M. So no issue there either.
This company has no product. Only hopes and promises alongside with a billion shares to dump
Links have been provided. Use Google if more info is desired.
End of discussion.
Promescent is the clear leader in the PE market. Here is the guy that helped them claim the top spot--Greg Kaminski.
Absorption Pharmaceuticals
Vice President, Marketing
Absorption Pharmaceuticals
June 2011 – May 2016 (5 years)
Responsible for all marketing activities, with a focus on digital. Played key role in establishing Promescent as the leading product in the U.S. for the treatment of premature ejaculation.
* Managed all ecommerce website activity - retail and wholesale
* Created all website content with a focus on driving search traffic
* Website ranks on the first page of Google search for > 90% of target keywords
* Worked with key influencers in the medical community to help establish Promescent as first-line therapy for PE among urologists and top medical institutions across the U.S.
* Worked with PR firms to generate press and, in some cases, wrote articles for publication
* Managed Amazon Channel
* Recently established presence on Google's PLA platform (i.e. Google Shopping)
* Responsible for digital advertising programs
* Created specifications for next generation website to accommodate growth: international expansion, promotions, and various types of ecommerce optimization and reporting
They are CLEARLY the top seller on Amazon. One can buy this product at Rite-Aid and Target.
Anyone can submit a better selling product if they can find one.
The report recognizes the following companies as the key players in the Global Premature Ejaculation Market: Absorption Pharmaceuticals LLC Furiex Pharmaceuticals Inc., Innovus Pharmaceuticals Inc. and Plethora Solutions Ltd.
That is great news that they are selling well it means that the market for (PE) is vast and wide as well as (ED)! There are too many players to point out in this market(Viaderma is now one of them), for you to be saying a company of promescents market value is a leader, it is unfounded. There product is sounds fantastic, but like you were saying another company with billions of dollars in market cap now has their product(sucks) doesn't seem so positive in retrospect. Now lets see what happens to viaderma share price of .02, when they have multiple products coming out into very popular markets. Viaderma Will be competing against Promescent and MANY others. who cares. Sorry that all the market players were not put into the PR. haha
© 2017 InvestorsHub.Com, Inc.
We are talking two separate types of ED. The article below summarizes the differences quite well.
http://www.businesswire.com/news/home/20160128006102/en/Promescent%C2%AE-Premature-Ejaculation-Takes-Lead-1-Seller
According to Daily Med, Promescent has been on the market since 2013.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b508238-3be7-4b0d-bf35-51de79f58f55
Ron Gilbert, one of the three named inventors of this patented product/process was murdered that year. Since he lived and worked in SoCal, I would think Otiko would know of him and his product.
The Patent
https://www.google.com/patents/WO2010085589A3?cl=en&dq=ininventor:ronald+ininventor:gilbert&hl=en&sa=X&ei=xdC2VOj7GojgsASykoCIBg&ved=0CB8Q6AEwAA
The Article
https://www.google.com/patents/WO2010085589A3?cl=en&dq=ininventor:ronald+ininventor:gilbert&hl=en&sa=X&ei=xdC2VOj7GojgsASykoCIBg&ved=0CB8Q6AEwAA
Also of note, the Promescent manufacturer just initiated a lawsuit against the British biz that sells competitive product K-Y Duration for trade secret theft.
https://globenewswire.com/news-release/2017/03/08/933502/0/en/Absorption-Pharmaceuticals-Maker-of-Premature-Ejaculation-Medication-Promescent-Files-Suit-Against-British-Conglomerate-for-Trade-Secret-Theft-and-Fraud.html
It is interesting to see competitor pricing and reviews as a benchmark. I wonder why Otiko mentioned Viagra and Cialis as market leaders in sexual dysfunction, and didn't mention Promescent as the clear leader in the PE aspect of dysfunction. His announcement centered on a planned PE product. Is he also planning on competing with Viagra with an unannounced product?
Promescent is a topical male lidocaine formula which is recommended by an amazing 1300 urologists (not podiatrists lol) to help men manage ejaculation successfully. Its rapid absorption technology, in conjunction with the metered-dose spray bottle, enables men to control penile sensitivity in order to maintain optimum sexual performance.
Developed with a leading U.S. University's School of Pharmacy, Promescent is the only product on the market formulated to absorb below the surface of the skin where the nerve endings are located, so that you can stop premature ejaculation and enjoy longer lasting sex. It's so effective that it is now recommended by Men's Health, Esquire, and Men's Fitness.
Interesting. Promescent retails for $19.95-22.95 (1.3ml) and $84.95 (7.4ml).
I shared the CEO's projected revenue for 2017. It's higher for 2018 and 2019 (~$12 Million).
I think he knows something we don't know. They are bringing a hemp water to market. Consider the acquisition of 02Breathe, too. They have an existing lineup of CBD products and oxygen bars.
So to get to 3.8 million this year and it is April 8 your telling me elev8 coffee is going to do 16,033 dollars a day in sales everyday for the rest of the year you have got to be joking
Below is the clinical data for the top PE product on the U.S. market.
http://www.nature.com/ijir/journal/v28/n6/full/ijir201631a.html
what clinical trials you need?
He must have meant to say "no further dilution." The Transfer Agent is the compliance and validation source for shares issued to date.
What did Otiko say about these "clinical trials"? Where were they performed and what standards were used?
Whatarush and l spoke today and he confirmed to me that he talked to the co. and there will be no dillution, the cost, data studies, and clinical trials are already complete. Liscensing agreements will be released through upcoming PR's.
Oh and the annual report will be for 2016 year end but no current filings. Pretty farn awesome if you say so yourself oh myself. Glta and to all a great finish to your weekend. Good day!
VATE began operations in October 2016. They launched their coffee in January 2017. The CEO is projecting 2017 revenues of 3.8 million with a Gross Profit of 2,423,640.00 after cost of goods sold is subtracted.
What is Wanderport projecting for 2017? Certainly, in order to exceed VATE's financial performance, they must grow sales exponentially to rise above their 2016 revenues of $22,888 with a Gross Profit of 22,444.
Yes you have K-cups and we do not and you have 13 following elev8 on Facebook and we have 6,374 following us on Facebook you have 2 products for sale and we have 29 hmmmm I wonder who will have higher sales.
When would that expected profitability be reflected in financials?
That sounds extremely profitable
Take it up with the Transfer Agent. I simply shared the numbers they verified on the Company's OTC Profile. They were different on March 1, March 7, and March 31. Yes, the changes since March 1 do equal 20M.
The Annual Report will show the amounts issued and the dates.
Dilution has been minimal and has not been the 20 million in 3 weeks you keep posting. It was done prior to that I've watched l2 everyday there has been almost none since.
Sounds expensive. Expect much more dilution. Details behind these forward looking plans should be in Annual Report this week.
The Company has signed a LOI or letter of intent to work with a Canadian-based investment group with expertise in logistics that includes distribution for the new and anticipated products. The investment group will target sales for the new patent pending products to countries that have accepted "Medical Marijuana" and "Recreational Use" of cannabis products and technologies for delivery of CBD and THC. This group will also target countries that allow the "Clinical Studies" for medical testing such as the United Kingdom and other Asian countries.
Add compostable K-Cups.
VATE: YES
Competition:NO
Speaking for myself, I don't waste money on low nutrition, high-fat items like doughnuts, soda, cookies, candy, chemically-laden snacks. I don't use big shopping carts and load them up with crap.
It's all about lifestyle here.
I am VATE'S target market.
Thanks...I missed that on my speed read through 64 pages. Clearly, they have marketing and management expertise. I'm staying because their business plan is intelligent and timely. Still am blown away by the quality and comprensive nature of their Annual Report, their willingness to share details, revenue projections.
All things point to a company focused on success.
Well stated. I never buy cheap coffee simply because it's cheap. I buy the highest quality, fair-trade, preferably organic coffee in K-cup packaging. I appreciate bulk discounts and sale prices. That's when I stock up.
Even if they offered k-cups, I wouldn't buy Sapa coffee because it's not fair trade.
VATE thinks like a customer like me. We are aligned. I shop Whole Foods and avoid stores like Kroger.
Two patch reviews were added this week for a total of 10. All are 5 Stars.
https://painreliefmeds.com/product/cbd-topical-hemp-oil-patch
The URL was created September 2014. Copyright is 2017 and very similar to Blue Planet Solar system website created February 2015 and also copyrighted 2017.
Both sites were last updated January 2017. I recall reading Erickson is an owner in Blue Planet.
http://www.bpsolarllc.com
New website up? Don't recall seeing this one before...
saticsolar.com
The first FDA-approved OTC spray for PE appears to be a success. It is available on the company website, Amazon, at Target and Walmart.
http://www.medicaldaily.com/penis-spray-better-sex-life-promescent-claims-treat-premature-ejaculation-396154
Promescent Reviews
http://www.risingmaster.com/promescent-review
www.absorptionpharmaceuticals.com
Promescent is the only PE Spray sold in the U.S. with clinical data to support its effectiveness. Data link is below.
Will Otiko reveal his clinical info?
http://www.nature.com/ijir/journal/v28/n6/full/ijir201631a.html
Hmmm...Maybe they will report MORE than 25M in Assets?
Well, that's one way to look at it. In light of the 26.47% shares reported as short sales today, I think it's likely CDEL didn't pay for them...YET.
Ground has thawed, oil is flowing, cannabis is growing, birds are singing.
Life is good.
http://otcshortreport.com/?index=CGRA&action=view
LMFAO!! (-21.3%) on 7.4 Million shares, with the vast majority of the volume being dumps into ever lower bids is a positive thing?